
The High Price of 'Miracles': Why Retatrutide Is a Public Health Gamble
A critical analysis of Eli Lilly's new triple-agonist weight loss drug, Retatrutide. We examine the cardiac risks, economic disparities, and the dangerous shift toward medicalizing...














